<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: <z:chebi fb="0" ids="27881">Resveratrol</z:chebi> has been demonstrated to be protective in the cardiovascular system </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to assess the effects of <z:chebi fb="0" ids="27881">resveratrol</z:chebi> on <z:chebi fb="17" ids="16240">hydrogen peroxide</z:chebi> (<z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi>)-induced increase in late <z:chebi fb="199" ids="26708">sodium</z:chebi> current (I(Na.L)) which augmented the reverse <z:chebi fb="0" ids="29101">Na(+)</z:chebi>-Ca(2+) exchanger current (I(NCX)), and the diastolic intracellular Ca(2+) concentration in ventricular myocytes </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: I(Na.L), I(NCX,) L-type Ca(2+) current (I(Ca.L)) and intracellular Ca(2+) properties were determined using whole-cell patch-clamp techniques and dual-excitation fluorescence photomultiplier system (IonOptix), respectively, in rabbit ventricular myocytes </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:chebi fb="0" ids="27881">Resveratrol</z:chebi> (10, 20, 40 and 80 µM) decreased I(Na.L) in myocytes both in the absence and presence of <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> (300 µM) in a concentration dependent manner </plain></SENT>
<SENT sid="4" pm="."><plain>Ranolazine (3-9 µM) and <z:chebi fb="2" ids="9506">tetrodotoxin</z:chebi> (<z:chebi fb="0" ids="9506">TTX</z:chebi>, 4 µM), I(Na.L) inhibitors, decreased I(Na.L) in cardiomyocytes in the presence of 300 µM <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> (300 µM) increased the reverse I(NCX) and this increase was significantly attenuated by either 20 µM <z:chebi fb="0" ids="27881">resveratrol</z:chebi> or 4 µM ranolazine or 4 µM <z:chebi fb="0" ids="9506">TTX</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, 10 µM <z:chebi fb="0" ids="27881">resveratrol</z:chebi> and 2 µM <z:chebi fb="0" ids="9506">TTX</z:chebi> significantly depressed the increase by 150 µM <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> of the diastolic intracellular Ca(2+) fura-2 fluorescence intensity (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFI</z:e>), fura-fluorescence intensity change (△<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFI</z:e>), maximal velocity of intracellular Ca(2+) transient rise and decay </plain></SENT>
<SENT sid="7" pm="."><plain>As expected, 2 µM <z:chebi fb="0" ids="9506">TTX</z:chebi> had no effect on I(Ca.L) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="27881">Resveratrol</z:chebi> protects the cardiomyocytes by inhibiting the <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi>-induced augmentation of I(Na.L.)and may contribute to the reduction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced lethal <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
</text></document>